 | |
 | |
| Clinical data | |
|---|---|
| Routes of administration | Vaporized, insufflated, injected, orally |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Excretion | Urine |
| Identifiers | |
| CAS Number |
|
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.024.630  |
| Chemical and physical data | |
| Formula | C10H13NO |
| Molar mass | 163.22 g/mol g·mol−1 |
| 3D model (JSmol) | |
| Chirality | Racemic mixture |
(
Methcathinone /ˌmɛθˈkæθɪˌnoʊn/ (α-methylamino-propiophenone or ephedrone) (sometimes called "cat" or "jeff" or "catnip" or "M-Kat" or "kat" or "intash" ) is a monoamine alkaloid and psychoactive stimulant, a substituted cathinone. It is used as a recreational drug due to its potent stimulant and euphoric effects and is considered to be addictive, with both physical and psychological withdrawal occurring if its use is discontinued after prolonged or high-dosage administration. It is usually snorted, but can be smoked, injected, or taken orally.
Methcathinone is listed as a Schedule I controlled substance by the Convention on Psychotropic Substances and the United States' Controlled Substances Act, and as such it is not considered to be safe or effective in the treatment, diagnosis, prevention, or cure of any disease, and has no approved medical use. Possession and distribution of methcathinone for the purpose of human consumption is illegal under any/all circumstances in the United States and is either illegal or highly regulated in most jurisdictions worldwide.
History
Methcathinone was first synthesized in 1928 in the United States and was patented by Parke-Davis in 1957. It was used in the Soviet Union during the 1930s and 1940s as an anti-depressant (under the name Эфедрон—ephedrone). Methcathinone has long been used as a drug of abuse in the Soviet Union and Russia.
Circa 1994, the United States government recommended to the UN Secretary-General that methcathinone should be listed as a Schedule I controlled substance in the Convention on Psychotropic Substances.
In parts of Europe methcathinone is not listed as a dangerous drug. In the United Kingdom it is listed as a Class B drug, but the Home Office is considering reclassifying it as Class A when it is dissolved in water for injection, as amphetamine is.
Chemistry
Methcathinone is a beta-keto N-methylamphetamine and is closely related to the naturally occurring compounds, cathinone and cathine. It is also very closely related to methamphetamine, differing by only the β-ketone substituent and differing from amphetamine
by both a keto and N-methyl substituent. Its carbon skeleton is
identical to pseudoephedrine and methamphetamine. It differs from
pseudoephedrine in that the hydroxide beta to the aromatic ring is
oxidized to a ketone.
Methcathinone possesses a chiral carbon atom, and therefore two
enantiomers are possible. When it is made semi-synthetically from
pseudo/ephedrine as a starting material, then only a single enantiomer
is produced. Given that the chiral center has an alpha hydrogen and adjacent the carbonyl group, the molecule will racemize in solution via an enol intermediate. This process is known as keto–enol tautomerism.
Methcathinone production utilizes the oxidation of pseudoephedrine or ephedrine, the former being preferred because of much higher yields achieved. Oxidation of pseudoephedrine to methcathinone requires little chemistry experience, making it (relatively) easy to synthesize. Potassium permanganate (KMnO4) is most commonly used as the oxidant.
In clandestine laboratories, synthesizing methcathinone using
potassium permanganate is considered undesirable because of the low
yields and the high toxicity of this oxidant, however, if done in a
proper laboratory using the proper procedures potassium permanganate can
be a high-yielding reactant. A method that yields more methcathinone is
oxidizing (pseudo)ephedrine with chromium (VI) compounds.
Methcathinone as free base is very unstable; it easily loses its ketone group, which is substituted with a hydroxyl group, yielding pseudoephedrine,
in the reverse of the typical synthesis reaction. Structurally, this
occurs when the C=O bond at the Rβ-position is converted into a C-OH
bond. Additionally, a dimerization reaction has been observed in
solutions of freebase methcathinone, which yields a biologically
inactive compound.
Effects
Methcathinone hydrochloride increases spontaneous rodent locomotor activity, potentiates the release of dopamine from dopaminergic nerve terminals in the brain, and causes appetite suppression.
Users can easily forget to consume fluids leading to increased thirst
and dehydration. The effects of methcathinone are similar to those of methamphetamine, initially deemed to be less intense by the inexperienced user, and often more euphoric. The effects have been compared to those of cocaine, since it commonly causes hypertension (elevated blood pressure) and tachycardia (elevated heart rate).
Reported effects include:
- Feelings of euphoria
- Increased alertness
- Slurred speech
- Shaking of the limbs
- Increased heart rate
- Increased blood Pressure, risk of stroke or heart attack
- Increased empathy and sense of communication
- Both decreased and increased sexual function and desire
- Bruxism
The effects of methcathinone usually last from four to six hours.
Pharmacology
Methcathinone
has very strong affinities for the dopamine transporter and the
norepinephrine (noradrenaline) transporter. Its affinity for the
serotonin transporter is less than that of methamphetamine.
The C=O bond at the Rβ-position (directly right of the phenyl ring) is slightly polar, and as a result the drug does not cross the lipid blood–brain barrier quite as well as amphetamine. Nevertheless, it is a potent CNS stimulant and dopamine reuptake inhibitor. Chronic high dosage use may result in acute mental confusion ranging from mild paranoia to psychosis. These symptoms typically disappear quickly if use is stopped.
Anecdotal reports have provided some information on patterns of methcathinone use. The most common route of administration is via nasal insufflation (snorting). Other routes of administration include per os, IV injection and smoking.
Illicit usage
Methcathinone
binges resemble amphetamine binges in that the user may not sleep or
eat, and takes in little in the way of liquids. The methcathinone binge
is followed by long periods of sleep, excess eating, long-lasting
nosebleeds (insufflation of methcathinone is corrosive to the nasal mucosa in the same manner as its methamphetamine counterpart) and, in some cases, depression.
Addiction
In preclinical studies, methcathinone hydrochloride produces an abuse potential similar to that of the amphetamines.
Methcathinone can be highly psychologically addictive, and can produce a methamphetamine-like withdrawal, which is somewhat less in intensity than methamphetamine.
In drug discrimination studies, methcathinone hydrochloride evokes responses similar to those induced by both dextroamphetamine sulfate and cocaine hydrochloride. When examined in particular pharmacological assays for psychomotor stimulant-like activity, both the dextrorotary and levorotary enantiomeric
forms of methcathinone hydrochloride have been found to be
pharmacologically active. In these assays, the l-form of methcathinone
is more active than either d-methcathinone or dextroamphetamine (this is
notable as the dextrorotary isomer is the more active isomer of both
amphetamine and methamphetamine).
Some street dealers are selling methcathinone as
dextroamphetamine or methamphetamine but the drug is more dangerous to
people who inject it than the more common amphetamine.
Intravenous usage
Injecting this substance has recently been associated with symptoms similar to those seen in patients with Parkinson's Disease (Manganism) due to the compound manganese dioxide which is a byproduct of synthesis with permanganate.
Clinical use
The Convention on Psychotropic Substances lists methcathinone as a Schedule I substance.
- In the United States, methcathinone is listed as a Schedule I drug, for which there is no clinical use.
- In the Netherlands, methylcathinone is listed as a Level I substance of the Opium Law, for which there is no clinical use.
- In the United Kingdom, methcathinone is listed as a Class B drug with no clinical uses.
